



IFW

Docket No.: 14090-00005-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Walter Stunkel et al.

Application No.: 10/577,219

Confirmation No.:

Filed: April 26, 2006

Art Unit: N/A

For: BIARYL LINKED HYDROXAMATES:
PREPARATION AND PHARMACEUTICAL
APPLICATIONS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 14090-00005-US1. A duplicate copy of this paper is enclosed.

Dated: August 8, 2006

Respectfully submitted,

By 

Donald K. Drummond

Registration No.: 52,834

CONNOLLY BOVE LODGE & HUTZ LLP


1990 M Street, N.W., Suite 800

Washington, DC 20036

(202) 331-7111

(202) 293-6229 (Fax)

Attorney for Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/577,219
				Filing Date	April 26, 2006
				First Named Inventor	Walter Stunkel et al.
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	14090-00005-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-6,552,065 B2	04-22-2003	REMISZEWSKI et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	2	WO 03/066579 A2	08-14-2003	AXYS PHARMACEUTICALS		
	3	WO 01/38322 A1	05-31-2001	METHYLGENE, INC.		
	4	WO 04/013130 A1	02-12-2004	ARGENTA DISCOVERY LIMITED		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	5	WADE, P.A., "Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin", Hum. Mol. Genet. Vol. 10, No. 7, Pgs. 693-698, (2001)		
	6	DE RUIJTER, A.J.M. et al, "Histone deacetylases (HDACs): characterization of the classical HDAC family", Biochem. J., 370, Pgs. 737-749, (2003)		
	7	RICHON, V.M. et al, "Second generation hybrid polar compounds are potent inducers of transformed cell differentiation", Proc. Natl. Acad. Sci. USA, Vol. 93, Pgs. 5705-5708, (1996)		
	8	RICHON, V.M. et al, "A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases", Proc. Natl. Acad. Sci. USA, Vol. 95, Pgs. 3003-3007, (1998)		
	9	BUTLER, L.M. et al, "Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells <i>in vitro</i> and <i>in vivo</i> " ¹¹ , Cancer Res. Vol. 60, Pgs. 5165-5170, (2000)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
-----------------------	--------------------

478177



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/577,219
				Filing Date	April 26, 2006
				First Named Inventor	Walter Stunkel et al.
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	14090-00005-US1

10	YOSHIDA, M. et al, "Potent and Specific Inhibition of Mammalian Histone Deacetylase Both <i>in Vivo</i> and <i>in Vitro</i> by Trichostatin A", J. Biol. Chem., Vol. 265, No. 28, Pgs. 17174-17179, (1990)
11	KIJIMA, M. et al, "Trapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreversible Inhibitor of Mammalian Histone Deacetylase", J. Biol. Chem., Vol. 268, No. 30, Pgs. 22429-22435, (1993)
12	BOUCHAIN, G. et al, "Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors", J. Med. Chem., Vol. 46, Pgs. 820-830 (2003)
13	STEFFAN, J.S. et al, "Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in <i>Drosophila</i> ", Nature, Vol. 413, (6857), Pgs. 739-743, October 18, 2001
14	SCHINDLER et al., "Dissociation between Interleukin -1 β mRNA and Protein Synthesis in Human Peripheral Blood Mononuclear Cells", J. Biol. Chem., Vol. 265, No. 18, Pgs. 10232-10237, (1990)
15	J. Taunton et al, "A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p", Science 1996 Vol. 272, Pgs. 408-411
16	CARBALLO et al, "Feedback Inhibition of Macrophage Tumor Necrosis Factor- α Production by Tristetraprolin", Science, Vol. 281, Pgs. 1001-1005, August 14, 1998
17	DINARELLO, C.A. and MOLDAWER, L.L. "Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis", A primer for clinicians, 3 rd Edition 2002, Amgen Inc., Pgs. 1-351
18	REMISZEWSKI, S.W. et al., "Inhibitors of Human Histone Deacetylase: Synthesis and Enzyme and Cellular Activity of Straight Chain Hydroxamates," Journal of Medical Chemistry, Vol. 45, No. 4, Pgs. 753-757, February 14, 2002
19	BLAGOSKLONNY, MV, "Prospective strategies to enforce selectively cell death in cancer cells", Oncogene, Vol. 23, No. 16, Pgs. 2967-2975, (2004)
20	KAUFMANN, S. H. et al., "Induction of Apoptosis by cancer chemotherapy", Experimental Cell Research, Vol. 256, Pgs. 42-49 (2000)
21	TIECHER, PH.D., B. A., "In Vivo Tumor Response End Points", Tumor Models in Cancer Research, Pgs. 593-616, 2002
22	SHEHA, M.M. et al., "Synthesis of Chelating Oxazole Derivatives with Potential Biological Activity", Egypt J. Pharm. Sci, No. 4-6, Pgs. 711-730 (1993)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--